Article and Video CATEGORIES
Please Note: New Treatments Have Emerged Since this Original Post
Drs. H. Jack West, Medical Director - Thoracic Oncology Program at Swedish Cancer Institute, President and CEO of GRACE, Karen Kelly - Associate Director for Clinical Research at UC Davis Comprehensive Cancer Center, and Sandip Patel - Medical Oncologist and Associate Professor of Medicine at Moores Cancer Center, UC San Diego Health, gathered post meeting to discuss new information from ASCO 2018 regarding lung cancer.
In this roundtable video, the doctors discuss Tarceva combined with carboplatin and Alimta, if it is given upfront will it affect the pace of the disease?
GRACE thanks the following sponsors for their support.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…